European Commission Approves DAYBU® as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Acadia Pharmaceuticals Announces DAYBUE® STIX is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces DAYBUE® STIX is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Steadright Critical Minerals Inc. to Acquire up to 75% Interest in the Péribonka Ree-Niobium Carbonatite Project, Saguenay-Lac-St-Jean Region, Québec
Prismo Metals Announces Listing of Blade Resources on the CSE Prismo Metals Owns 6,755,000 Shares of Blade Resources
Goldgroup Highlights Its Two Producing Mines and Significant Growth Potential Across the Don David Gold Complex in Mexico
